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Summary
Background Tuberculosis is a major contributor to the global burden of disease, causing more than a million deaths 
annually. Given an emphasis on equity in access to diagnosis and treatment of tuberculosis in global health targets, 
evaluations of differences in tuberculosis burden by sex are crucial. We aimed to assess the levels and trends of the 
global burden of tuberculosis, with an emphasis on investigating differences in sex by HIV status for 204 countries 
and territories from 1990 to 2019.
Methods We used a Bayesian hierarchical Cause of Death Ensemble model (CODEm) platform to analyse 21 505 site-
years of vital registration data, 705 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, 
and 680 site-years of mortality surveillance data to estimate mortality due to tuberculosis among HIV-negative 
individuals. We used a population attributable fraction approach to estimate mortality related to HIV and tuberculosis 
coinfection. A compartmental meta-regression tool (DisMod-MR 2.1) was then used to synthesise all available data 
sources, including prevalence surveys, annual case notifications, population-based tuberculin surveys, and tuberculosis 
cause-specific mortality, to produce estimates of incidence, prevalence, and mortality that were internally consistent. We 
further estimated the fraction of tuberculosis mortality that is attributable to independent effects of risk factors, 
including smoking, alcohol use, and diabetes, for HIV-negative individuals. For individuals with HIV and tuberculosis 
coinfection, we assessed mortality attributable to HIV risk factors including unsafe sex, intimate partner violence (only 
estimated among females), and injection drug use. We present 95% uncertainty intervals for all estimates.
Findings Globally, in 2019, among HIV-negative individuals, there were 1·18 million (95% uncertainty interval 
1·08–1·29) deaths due to tuberculosis and 8·50 million (7·45–9·73) incident cases of tuberculosis. Among 
HIV-positive individuals, there were 217 000 (153 000–279 000) deaths due to tuberculosis and 1·15 million (1·01–1·32) 
incident cases in 2019. More deaths and incident cases occurred in males than in females among HIV-negative 
individuals globally in 2019, with 342 000 (234 000–425 000) more deaths and 1·01 million (0·82–1·23) more incident 
cases in males than in females. Among HIV-positive individuals, 6250 (1820–11 400) more deaths and 
81 100 (63 300–100 000) more incident cases occurred among females than among males in 2019. Age-standardised 
mortality rates among HIV-negative males were more than two times greater in 105 countries and age-standardised 
incidence rates were more than 1·5 times greater in 74 countries than among HIV-negative females in 2019. The 
fraction of global tuberculosis deaths among HIV-negative individuals attributable to alcohol use, smoking, and 
diabetes was 4·27 (3·69–5·02), 6·17 (5·48–7·02), and 1·17 (1·07–1·28) times higher, respectively, among males than 
among females in 2019. Among individuals with HIV and tuberculosis coinfection, the fraction of mortality 
attributable to injection drug use was 2·23 (2·03–2·44) times greater among males than females, whereas the fraction 
due to unsafe sex was 1·06 (1·05–1·08) times greater among females than males.
Interpretation As countries refine national tuberculosis programmes and strategies to end the tuberculosis epidemic, the 
excess burden experienced by males is important. Interventions are needed to actively communicate, especially to men, 
the importance of early diagnosis and treatment. These interventions should occur in parallel with efforts to minimise 
excess HIV burden among women in the highest HIV burden countries that are contributing to excess HIV and 
tuberculosis coinfection burden for females. Placing a focus on tuberculosis burden among HIV-negative males and 
HIV and tuberculosis coinfection among females might help to diminish the overall burden of tuberculosis. This strategy 
will be crucial in reaching both equity and burden targets outlined by global health milestones.
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Introduction
Tuberculosis is an important contributor to morbidity 
and mortality globally.1 Despite being preventable and 
treatable, tuberculosis is a leading cause of death from a 
single infectious agent.2,3 The Sustainable Development 
Goals (SDGs) and the WHO End TB Strategy have 
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defined targets for ending the tuberculosis epidemic 
that aim to reduce tuberculosis mortality by 95% and 
incidence by 90% by 2035.4,5 An understanding of the 
trends in tuberculosis burden is crucial to evaluate 
progress towards ending the epidemic and informing 
policy and programmes.
Despite an emphasis on equity in access to tuberculosis 
diagnosis and treatment by the WHO End TB Strategy, 
differences in tuberculosis burden by sex have received 
little attention. The available evidence indicates that men 
are less likely to seek or have access to tuberculosis care 
than women.6–8 A systematic review and meta-analysis 
of tuberculosis prevalence surveys in 28 countries 
found that males have 2·21 times higher prevalence of 
bacteriologically confirmed tuberculosis than females.6 
For global case notifications, studies have estimated that 
males have a 50–70% higher incidence rate than females 
in selected low-income and middle-income countries.6,9 
Although previous Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD)2,10 and WHO3 tuberculosis 
modelling efforts have presented sex-specific tuberculosis 
burden estimates, there has yet to be a systematic 
comparable quantification of these sex differences by 
HIV status, along with the contribution of modifiable 
risk factors. Few global sex differences are observed in 
age-adjusted prevalence of latent tuberculosis infection;11 
this finding is a possible indicator that men have 
heightened exposure to risk factors for the development 
of active tuberculosis that might partially explain the sex 
differences. One study found that cigarette consumption 
explains 33% of the variation in the sex ratio of 
tuberculosis notifications.12 Although indicative, other 
important risk factors for tuberculosis, such as diabetes, 
alcohol consumption, and HIV infection, have yet to be 
considered in analyses of sex differences at the global 
level.
For GBD 2019, we assess the levels and trends of the 
global burden of tuberculosis, with an emphasis on 
investigating differences by sex. We focus on reporting 
tuberculosis mortality and incidence by HIV status and 
sex from 1990 to 2019, for 204 countries and territories. 
We also analyse how sex differences vary by the Socio-
demographic Index (SDI),13 a composite indicator based 
on income, education, and fertility. Finally, we estimate 
Research in context
Evidence before this study
Globally, tuberculosis is a leading cause of death from a single 
infectious agent, contributing more than a million deaths 
annually. The global sex-specific burden of tuberculosis has 
been estimated by various groups, including the WHO Global 
Tuberculosis Programme and the Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD). However, differences in 
the levels and trends of the global burden of tuberculosis by HIV 
status, along with the contribution of modifiable risk factors by 
sex, have not been extensively characterised. We searched 
PubMed with the terms “tuberculosis” AND (“burden” OR 
“estimates”) AND (“sex” OR “gender”) AND (“differences” OR 
“discrepancies” OR “disparities”), with no language restrictions, 
for publications up to Dec 17, 2020. Our search identified ten 
studies that reported population-based tuberculosis burden 
estimates and, of these studies, two closely examined sex 
differences. One of these studies quantified sex differences in 
tuberculosis prevalence surveys from 2001 to 2014 for selected 
countries. Neither of these studies systematically examined sex 
differences in tuberculosis mortality and incidence, along with 
the contribution of modifiable risk factors, over time.
Added value of this study
This iteration of GBD provides tuberculosis mortality and 
morbidity estimates for nine new small or island countries and 
territories (Cook Islands, Monaco, San Marino, Nauru, Niue, 
Palau, Saint Kitts and Nevis, Tokelau, and Tuvalu). It also 
includes many new data sources and a multitude of advances in 
tuberculosis modelling methods. Moreover, we report for the 
first time how sex differences vary by sociodemographic 
development and the burden of HIV and tuberculosis 
coinfection attributable to potentially modifiable HIV risk 
factors (unsafe sex, intimate partner violence, and injection 
drug use). We also report a detailed assessment of sex 
differences across different measures of tuberculosis burden 
disaggregated by HIV status to enhance understanding of 
excess tuberculosis burden by sex globally. Finally, we report for 
the first time age-standardised, risk-deleted mortality rates 
along with the male-to-female ratio of risk-deleted mortality 
rates. Our data confirm findings from previous studies that the 
burden of tuberculosis is greater in males than in females. 
We found that males experienced substantially greater 
tuberculosis burden globally, with many countries estimated to 
have 50% higher incidence and 100% higher mortality rates for 
males than for females among HIV-negative individuals. 
Across all sociodemographic development levels, tuberculosis 
mortality rates were consistently greater among HIV-negative 
males than HIV-negative females. Among individuals with HIV 
and tuberculosis coinfection, mortality was higher among 
females than males, with unsafe sex and intimate partner 
violence being large contributors to the differences in the 
countries with the highest HIV burden.
Implications of all the available evidence
Smoking, alcohol consumption, and timely access to 
tuberculosis services represent challenges and opportunities 
for reducing the excess burden of tuberculosis among men. 
Developing strategies to prevent tuberculosis among males, 
while also reducing the burden of HIV and tuberculosis 
coinfection, especially among females, will be crucial in 
achieving equity targets outlined by the WHO End TB 
Strategy.
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the percentage of tuberculosis deaths, among HIV-
negative individuals, attributable to the independent 
effects of risk factors including smoking, alcohol 
consumption, and diabetes. We also examine the 
proportion of deaths among people with HIV and 
tuberculosis coinfection that are attributable to HIV risk 
factors, including unsafe sex, intimate partner violence, 
and injection drug use.
Methods
Overview
Detailed methods for GBD and on tuberculosis estimation 
in GBD have been previously published.1,2,10 Here, we 
provide a brief description of the methods and estimation 
strategy for tuberculosis and risk factors. Detailed 
descriptions for each step of the estimation process with 
flow charts are provided in the appendix (pp 5–6). In 
compliance with the Guidelines for Accurate and 
Transparent Health Estimates Reporting, input data 
sources and code for each step of the estimation process 
are available on the Global Health Data Exchange. This 
manuscript was produced as part of the GBD Collaborator 
Network and in accordance with the GBD protocol.
Tuberculosis mortality
The GBD Cause of Death database collates all available 
data from vital registration systems, surveillance 
systems, and verbal autopsies. For modelling mortality 
due to tuberculosis among HIV-negative individuals, we 
included 21 505 site-years of vital registration data, 
705 site-years of verbal autopsy data, 825 site-years of 
sample-based vital registration data, and 680 site-years of 
mortality surveillance data. We processed raw data to 
reconcile discrepancies in coding schemes, redistribute 
garbage codes (eg, ill-defined codes and intermediate 
causes) to underlying causes of death, disaggregate data 
by age and sex, and adjust for misclassified HIV deaths.1
We modelled tuberculosis mortality among HIV-
negative individuals using the Cause of Death Ensemble 
model (CODEm) framework with separate models by 
sex.1,14 CODEm produces a wide range of submodels 
with different functional forms for the outcome variable 
(mortality rate or cause fraction), with varying combi-
nations of predictive covariates (eg, alcohol consumption, 
diabetes, smoking prevalence, and Healthcare Access 
and Quality [HAQ] Index15). A full list of covariates used 
in the CODEm framework can be found in the 
appendix (p 13). The ensemble of models was then 
selected on the basis of CODEm performance on out-of-
sample predictive validity tests. Tuberculosis mortality 
among HIV-positive individuals was estimated using a 
population attributable fraction approach consistent with 
previous GBD cycles.2,11
Tuberculosis morbidity
Consistent with previous GBD iterations,2,11 we 
used a Bayesian meta-regression modelling tool, 
DisMod-MR 2.11 to simultaneously model tuberculosis 
incidence, prevalence, and cause-specific mortality. 
Details on case definitions and how these data are 
processed are in the appendix (pp 3–4, 20–22).
We made several improvements to our modelling 
approach in GBD 2019. First, we standardised our 
approach to adjust prevalence data when the case 
definition was smear-positive tuberculosis rather than 
bacteriologically positive tuberculosis, using all available 
prevalence surveys that provided comparisons. We used 
the same approach to compute an adjustment factor to 
recalibrate studies that used symptoms only as a screening 
method compared with studies using both symptoms 
and chest x-ray during screening (appendix pp 21–22). 
Second, we used a novel Bayesian meta-regression 
method16 using age-sex-specific mortality-to-incidence 
ratios (logit transformed) from locations with high-quality 
data ratings on cause of death data as input. In our meta-
regression analysis, we used the HAQ Index15 as the 
primary covariate, with GBD super-region fixed effects. 
After model calibration, we predicted age-sex-specific 
mortality-to-incidence ratios as a function of the HAQ 
Index for all locations and years similar to the previous 
GBD iteration.11 Third, we used tuberculosis duration and 
excess mortality rate data as priors in our morbidity 
modelling strategy to help create coherent estimates in 
modelling (appendix pp 22–23).
We used age-sex-specific case notifications as input 
data for locations with high-quality data ratings on 
causes of death data,1 predicted mortality-to-incidence 
ratio-based incidence for locations with low-quality data 
ratings for causes of death data, prevalence survey data 
where available, and estimates of excess mortality 
rate, remission, and cause-specific mortality as input 
to DisMod-MR 2.117 to generate estimates that are 
consistent with each other. Sex-specific results were 
generated in DisMod-MR 2.1 by using sex-specific 
inputs and incorporating a covariate for sex. As in 
previous GBD iterations, we applied the proportion of 
cases of HIV and tuberculosis coinfection among all 
cases of tuberculosis to incidence and prevalence to 
distinguish between HIV and tuberculosis coinfection 
and tuber culosis without HIV.4,11
Risk factors
Methods for risk factor attribution to tuberculosis 
disaggregated by HIV status have previously been 
published in detail.10,18 Briefly, we included risk–outcome 
pairs with convincing or probable evidence to compute the 
proportion of disease burden attributable to risk factors by 
estimating the relative risk of the outcome as a function of 
exposure values, estimating the global prevalence of 
exposures, and determining the theoretical minimum 
risk exposure level (TMREL) using all available global 
data sources (appendix pp 138–170). Next, estimates of 
attributable mortality were computed by multiplying 
the number of tuberculosis deaths by the population 
For input data sources and code 
see http://ghdx.healthdata.org/
gbd-2019/data-input-sources
See Online for appendix
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attributable fraction (PAF) for the risk–outcome pair for a 
given age, sex, location, and year. The PAF is the fraction of 
tuberculosis deaths that would be reduced if the exposure 
to the risk factor was at the TMREL. In addition to PAFs, 
we computed risk-deleted mortality rates, defined as the 
death rate that would had been observed if the risk factors 
of interest were set to their TMREL.18 For tuberculosis 
among HIV-negative individuals, we examined the 
fractions of deaths attributable to alcohol consumption, 
smoking, and diabetes. For HIV and tuberculosis 
coinfection, we focused on the fractions of deaths 
attributable to HIV risk factors including unsafe sex, 
intimate partner violence (only estimated among females), 
and injection drug use.
SDI and data presentation
The SDI is a composite indicator, ranging from 0 to 1, of 
a country’s total fertility rate for individuals younger than 
25 years, average years of schooling, and lag-distributed 
income per capita.1 The index was categorised by 
quintiles using country-level estimates of the SDI 
in 2019. To investigate differences by sex, we present 
male-to-female (sex) ratios as the quotient of tuberculosis 
burden in males divided by tuberculosis burden in 
females. These ratios were computed for tuberculosis 
mortality rates, incidence rates, and PAFs. We use the 
GBD world population age standard to derive age-
standardised rates for mortality and incidence. We 
present 95% uncertainty intervals (UIs) for every 
tuberculosis estimate based on the 2·5th and 
97·5th percentiles of the posterior distributions that are 
carried over from each step in analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Globally, in 2019, among HIV-negative individuals, we 
estimated that there were 8·50 million (95% UI 7·45–9·73) 
tuberculosis incident cases and 1·18 million (1·08–1·29) 
deaths due to tuberculosis. In 1990, these figures were 
8·76 million (7·59–10·06) tuberculosis incident cases 
and 1·78 million (1·63–1·92) deaths. Among HIV-positive 
individuals, we estimated that there were 1·15 million 
(1·01–1·32) tuberculosis incident cases and 217 000 
(153 000–279 000) deaths due to tuberculosis in 2019 
(appendix pp 62–77). The corresponding figures in 1990 for 
HIV-positive individuals were 507 000 (449 000–571 000) 
cases and 119 000 (89 700–159 000) deaths. Overall, HIV and 
tuberculosis coinfection constituted 12·0% (11·3–12·4) 
of the global 9·65 million (8·48–11·03) incident cases of 
tuberculosis and 15·5% (9·6–21·3) of the global 
1·40 million (1·28–1·53) deaths due to tuberculosis in 2019.
Globally, in 2019, more incident cases and deaths 
occurred in males than in females among HIV-negative 
individuals, with 1·01 million (95% UI 0·82–1·23) more 
incident cases and 342 000 (234 000–425 000) more 
deaths among males than females (table). Among HIV-
positive individuals, however, 81 100 (63 300–100 000) more 
incident cases and 6250 (1820–11 400) more deaths 
occurred among females than among males (appendix p 62). 
Globally, 56·0% (54·4–57·5) of incident cases and 
64·5% (59·8–67·8) of deaths occurred among males 
in 2019.
In HIV-negative people, the global age-standardised 
tuberculosis incidence rate per 100 000 population in 2019 
was 120 (95% UI 105–136) among males and 94·9 (83·0–109) 
among females, and the global age-standardised 
tuberculosis mortality rate per 100 000 population was 
19·7 (17·9–21·6) among males and 10·1 (8·81–12·1) among 
females (table). At the regional level, among HIV-negative 
individuals, age-standardised incidence rates were nearly 
two times higher in eastern Europe, tropical Latin America, 
and central Europe, and age-standardised mortality rates 
were more than three times higher in eastern Europe, 
central Europe, and southern sub-Saharan Africa, among 
males than among females.
Among HIV-positive individuals, the global age-stan-
dardised tuberculosis incidence rate per 100 000 popu-
lation in 2019 was 13·2 (95% UI 11·6–15·0) among 
males and 15·5 (13·5–17·7) among females, and the 
global age-standardised tuberculosis mortality rate per 
100 000 popu lation was 2·61 (1·83–3·35) among 
males and 2·81 (1·98–3·60) among females (appendix 
pp 61–75). The regions where males with HIV had the 
largest relative excess burden compared with females 
with HIV were in high-income Asia Pacific, Australasia, 
and central Latin America for both incidence and morta-
lity, but females had higher age-standardised rates for 
both measures in almost every GBD region in Africa.
The majority of incident cases (78·0% [95% UI 
73·5–81·8]) and deaths (58·3% [56·8–59·8]) in 2019 
were in individuals aged 15–64 years (figure 1). For 
tuberculosis incidence among HIV-negative individuals, 
females had slightly greater numbers of incident cases 
for age groups younger than 25 years, but more incident 
cases occurred in males throughout most adult age 
groups. The differences between sexes became smaller 
in the older age groups. For tuberculosis mortality in 
HIV-negative individuals, trends were similar to 
those observed for incident infections, but compared 
with females, males had more deaths starting at age 
15–19 years (figure 1). Among HIV-positive people, 
females generally had more cases and deaths than males 
in the reproductive age groups, in which most cases and 
deaths occurred (appendix p 46).
Figure 2 shows trends in age-standardised tuberculosis 
mortality rate per 100 000 population among HIV-
negative individuals and HIV-positive individuals by SDI 
quintile and sex. Across SDI quintiles, sharp declines in 
age-standardised tuberculosis mortality from 1990 to 2019 
occurred in both males and females among HIV-negative 
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Incidence Mortality
Female cases Rate 
(per 100 000 
females)
Male cases Rate 
(per 100 000 
males)
Female deaths Rate 
(per 100 000 
females)
Male deaths Rate 
(per 100 000 
males)
Global 3 740 000 
(3 270 000–4 310 000)
94·9 
(83·0–109)
4 750 000 











Low SDI 938 000 















Low-middle SDI 1 460 000 
(1 260 000–1 700 000)
170 
(148–196)
1 660 000 











Middle SDI 1 020 000 
(897 000–1 160 000)
83·3 
(73·2–94·5)
1 340 000 






























































































































































































































































































































South Asia 1 750 000 
(1 500 000–2 040 000)
201 
(174–232)
2 070 000 
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(Table continues on next page)
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individuals. Males consistently had higher mortality than 
females across the time period. Although the relative gap 
between males and females without HIV declined for the 
high SDI quintile, the gap remained the same or slightly 
increased in the remaining SDI quintiles (appendix p 41). 
For people with HIV and tuberculosis coinfection, there 
were sharp declines in age-standardised mortality after 
each SDI quintile’s peak in tuberculosis mortality. In the 
high SDI and high-middle SDI quintiles, males with 
HIV and tuberculosis coinfection consistently had higher 
mortality than females. In the low and middle SDI 
quintiles, however, females with HIV and tuberculosis 
coinfection had higher mortality than males throughout 
most of the time series. The relative gap between females 
and males diminished substantially in the low and 
middle SDI quintiles after peaks in HIV and tuberculosis 
coinfection mortality (appendix p 41).
Among HIV-negative individuals, age-standardised 
tuber culosis incidence rates were more than 300 per 
100 000 popu lation in 21 countries for males and in 
ten countries for females (appendix pp 42, 48–61). Age-
standardised tuberculosis mortality rates were more than 
100 per 100 000 population in 19 countries for males and in 
three for females (appendix pp 43, 48–61). Among HIV-
positive individuals, the estimated age-standardised 
incidence rate was more than 300 per 100 000 population in 
eight countries for females and four for males (appendix pp 
44, 62–77). There were similar sex differences in mortality 
in people with HIV and tuberculosis coinfection: nine 
countries had an estimated age-standardised mortality rate 
of more than 50 per 100 000 population for females 
compared with eight countries for males (appendix pp 45, 
62–77).
Figure 3 maps the ratio between males and females for 
age-standardised incidence rates and mortality rates for 
tuberculosis in HIV-negative individuals in 2019. 
74 countries had age-standardised incidence rates that 
were at least 1·5 times greater and 21 countries had age-
standardised incidence rates that were at least two times 
greater among males than females. The countries with the 
largest ratios between males and females for age-
standardised incidence rates were Armenia, Trinidad 
and Tobago, Guyana, Ukraine, and Belarus. For age-
standardised mortality rates, 105 countries had rates more 
than two times greater and 17 countries had rates more 
than four times greater among males than females. 
Armenia, Georgia, Ukraine, Saint Vincent and the 
Grenadines, and Moldova had the greatest ratios in age-
standardised mortality rates between males and females in 
2019. The ratios between males and females for age-
standardised incidence and mortality were similar between 
countries with high and low estimated tuberculosis 
burdens among HIV-negative individuals. For example, 
the respective ratios for incidence and mortality were 1·81 
(95% UI 1·76–1·88) and 3·04 (2·12–3·98) for China, 1·77 
(1·70–1·84) and 2·67 (1·84–3·72) for the Philippines, and 
1·24 (1·20–1·29) and 1·91 (1·34–2·62) for India, whereas 
the respective ratios in countries with lower tuberculosis 
burden were 1·62 (1·54–1·72) and 2·00 (1·80–2·17) for the 
USA, 1·61 (1·53–1·69) and 2·55 (2·30–2·96) for Japan, 
and 1·26 (1·16–1·37) and 1·55 (1·33–2·02) for Finland.
Among HIV-positive individuals, 66 countries and 
24 countries had age-standardised incidence rates that 
were more than two times and three times greater, 
respectively, among males than females (figure 4A). For 
age-standardised mortality rates, 87 countries and 
16 countries had rates that were more than two times 
and four times greater, respectively, among males than 
females (figure 4B). Countries where overall estimated 
HIV and tuberculosis coinfection burden was low 
had the largest male-to-female ratios. Conversely, the 
countries with the highest estimated HIV and 
tuberculosis coinfection burden (eg, Lesotho, Eswatini, 
Botswana, Zimbabwe, and South Africa) had 
Incidence Mortality
Female cases Rate 
(per 100 000 
females)
Male cases Rate 
(per 100 000 
males)
Female deaths Rate 
(per 100 000 
females)
Male deaths Rate 
(per 100 000 
males)
(Continued from previous page)
Sub-Saharan 
Africa
1 020 000 
(875 000–1 190 000)
209 
(182–239)
1 110 000 



















































































95% uncertainty intervals are shown in parentheses. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
Table: Tuberculosis incident cases and deaths and age-standardised rates of tuberculosis incidence and mortality per 100 000 population among HIV-negative males and females by GBD 
regions and SDI quintiles, 2019
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Figure 1: Global age-sex distribution of tuberculosis incident cases (A) and deaths (B) in HIV-negative individuals, 2019
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Figure 4: Male-to-female ratio of age-standardised incidence (A) and mortality (B) rates among HIV-positive individuals by geography, 2019
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male-to-female ratios between 0·90 and 1·24 for age-
standardised mortality, but these same countries had 
ratios below 1 for age-standardised incidence (ratios 
between 0·76 and 0·94). Overall, 35 and 56 countries had 
male-to-female ratios below 0·75 (female-to-male 
ratio 1·33) for age-standardised incidence and mortality 
among HIV-positive individuals, respectively.
Globally, in 2019, among HIV-negative individuals, the 
PAF of tuberculosis deaths due to alcohol was 17·76% 
(95% UI 11·60–22·83), due to smoking was 
15·52% (12·67–18·33), and due to diabetes was 10·20% 
(6·37–14·47). The global all-age PAFs for tuberculosis 
deaths due to alcohol, smoking, and diabetes were 
4·27 (3·69–5·02), 6·17 (5·48–7·02), and 1·17 (1·07–1·28) 
times higher, respectively, among males than females 
in 2019 (figure 5). The regions with the largest sex ratios 
in the PAF of tuberculosis deaths due to alcohol 
were in south Asia (11·20 [8·38–15·08]), north Africa and 
the Middle East (8·53 [6·66–11·53]), and east Asia 
(5·77 [4·32–7·81]); those due to smoking were in central 
sub-Saharan Africa (10·59 [8·61–13·08]), central Asia 
(9·80 [8·18–12·15]), and north Africa and the Middle East 
(8·86 [7·57–10·99]); and those due to diabetes were in 
central sub-Saharan Africa (1·44 [1·28–1·62]), high-
income Asia Pacific (1·36 [1·14–1·66]), and Oceania 
(1·34 [1·20–1·50]). If the combined effects of alcohol, 
smoking, and diabetes were removed, HIV-negative 
males would still have a modestly higher age-standardised 
mortality rate than HIV-negative females at the global 
level (sex ratio 1·28 [1·05–1·49]; appendix pp 104–18).
Among both male and female HIV-positive 
individuals in 2019, the global PAF of tuberculosis 
deaths due to unsafe sex was 82·47% (95% UI 
80·42–84·25), due to drug use was 5·59% (4·44–7·00), 
and due to intimate partner violence was 8·04% 
(4·22–12·42). The global all-age PAF for tuberculosis 
mortality in people with HIV due to injection drug use 
was 2·23 (2·03–2·44) times greater among males than 
females, and the PAF due to unsafe sex was 1·06 
(1·05–1·08) times greater among females than males 
(appendix p 47). The regions with the largest sex ratios 
in the PAF due to injection drug use between male and 
females with HIV were in east Asia (5·30 [4·00–6·85]), 
southeast Asia (5·05 [4·23–5·70]), and central 
Europe (3·02 [2·82–3·27]). Southern sub-Saharan 
Africa (19·71% [12·03–29·94]), central sub-Saharan 
Africa (18·95% [11·06–29·55]), and Oceania (17·41% 
[11·49–25·16]) are estimated to have the highest PAFs 
for intimate partner violence among females with HIV 
(appendix p 47). After removal of the combined effects 
Figure 5: All-age population attributable fractions of tuberculosis deaths due to alcohol use, diabetes, and smoking among HIV-negative men and women by 
GBD region, 2019
GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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of unsafe sex, injection drug use, and intimate partner 
violence, males with HIV would have a 1·21 (1·15–1·28) 
times higher global age-standardised tuberculosis 
mortality rate than females with HIV (appendix 
pp 119–33).
Discussion
GBD 2019 provides a comprehensive assessment of 
the global tuberculosis burden, with an emphasis on 
characterising sex differences across different metrics of 
tuberculosis burden. We found that age-standardised 
incidence rates among HIV-negative individuals were 
more than 1·5 times greater in 74 countries, and age-
standardised mortality rates were more than two times 
greater in 105 countries, in males than in females in 
2019. Among HIV-positive individuals, age-standardised 
incidence and mortality rates were 1·33 times larger in 
35 and 56 countries, respectively, for females than males.
These results align with the findings from previous 
studies that males have a greater burden of tuberculosis 
than females due to men exhibiting lower levels of 
health-care use, presenting more advanced stages of 
the disease when care is sought, and having poorer 
adherence to anti-tuberculosis treatment.8,19,20 Previous 
work has highlighted that men may delay seeking health 
care for tuberculosis-suggestive symptoms due to fear 
or to avoid diagnosis of a serious condition such as 
tuberculosis or HIV.20,21 These fears and anxieties 
intersect with masculinity expectations, wherein men 
face societal pressure to neglect symptoms to remain 
physically and financially strong and capable to satisfy 
leadership roles.22–24 The combination of late initiation of 
tuberculosis treatment and poor treatment adherence 
might be contributing to age-standardised mortality rates 
being nearly two times greater among males than among 
females in the GBD.
Risk factors are also important to the observed sex 
differences in tuberculosis mortality. Previous work has 
found that alcohol use25 and smoking12 are substantial 
contributors to sex differences in tuberculosis burden. 
The global fraction of tuberculosis deaths attributable to 
alcohol consumption and smoking was more than four 
times and six times higher, respectively, among males 
than among females. Despite the global diabetes 
prevalence being very similar for males and females,11 we 
found that the fraction of tuberculosis deaths attributable 
to diabetes was modestly higher for males. Some evidence 
suggests that the higher fraction among males might 
be due to men having poorer tuberculosis treatment 
outcomes than women in the presence of diabetes 
comorbidities.26,27 Together, the findings underscore that 
risk factors, particularly alcohol and smoking, along with 
late treatment initiation, are probably major contributors 
to the sex differences in tuberculosis mortality among 
HIV-negative people. Indeed, our results show that the 
excess tuberculosis mortality among males would 
decrease from 1·97 (95% UI 1·60–2·26) to 1·28 
(1·05–1·49) if the effects of risk factors for disease 
progression were removed. The heightened exposure to 
risk factors that contribute to disease progression among 
men might also be a factor for why males have 50% higher 
age-standardised incidence rates than females in more 
than 70 countries.
Although our study found that tuberculosis burden 
and risk factors are higher among males than females, 
the burden among females is still unnecessarily large; we 
estimated more than 500 000 deaths among HIV-negative 
and HIV-positive females in 2019. Evidence suggests that 
men indeed delay seeking health care for tuberculosis, 
contributing to poor case detection among men, but that 
women generally encounter more barriers to receiving 
appropriate tuberculosis care.19 Across various settings, 
women, compared with men, face a substantially longer 
time to tuberculosis diagnosis28–32 due to lower priority or 
attention paid when women present non-specific 
tuberculosis symptoms,19 evidence of tuberculosis 
diagnostic tools being less sensitive for women,33 and 
gender norms requiring women to negotiate with 
husbands to seek tuberculosis care.34
Moreover, we found that the global burden of 
tuberculosis was higher among females than among 
males in HIV-positive individuals. In the countries with 
the highest HIV and tuberculosis coinfection burden 
(eg, countries in southern sub-Saharan Africa), our 
results show that females generally had a greater HIV 
and tuberculosis coinfection burden than males, with 
unsafe sex and intimate partner violence being significant 
contributors. The larger incidence rates among females 
in these countries might be due to HIV disproportionately 
affecting women in countries with high HIV burden.35–37 
The larger burden of HIV among women, combined 
with HIV being the strongest risk factor for progression 
from latent to active tuberculosis,38 compounds the 
observed differences in these countries.
These findings underscore the need for HIV prevention 
and treatment to diminish HIV and tuberculosis coin-
fection burden. Interventions are needed that address 
multiple causes of women’s vulnerability to HIV 
infection, including poverty, exposure to intimate partner 
violence, cultural factors that disempower women, such 
as encouraging marriage to older men, and laws 
deterring reproductive health services.39–41
The End TB Strategy sought to reduce tuberculosis 
incidence to below 85 new cases per 100 000 population 
by 2020. However, our findings suggest that sub-
stantial additional progress needs to be made, with 
40 countries having age-standardised incidence rates 
greater than 170 per 100 000 population, more than 
double the target of 85 per 100 000, in 2019. Males are 
particularly at risk for not reaching this target, as the 
global age-standardised tuberculosis incidence rate for 
males without HIV was 120 per 100 000 population, 
compared with 95 per 100 000 population for HIV-
negative females in 2019. The excess tuberculosis burden 
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among men found in this study strengthens the view 
that men should be targeted in screening services and 
routine diagnostics6,8 to achieve equity targets outlined by 
the SDGs and End TB Strategy. Interventions are needed 
to engage men in tuberculosis care, with social 
protections (eg, prevention of loss of employment while 
receiving care and cash transfers) for families, while 
actively communicating the importance of early 
diagnosis to men.24 Interventions should also place 
efforts on improving communication and preventive 
strategies to support reducing behavioural risk factors 
such as alcohol use and smoking.
Although the results reported in GBD 2019 reflect 
tuberculosis burden before the emergence of the 
COVID-19 pandemic, the worldwide pandemic has 
important consequences for the global burden of 
tuberculosis that need to be investigated by tuberculosis 
programmes. Modelling studies have suggested that 
tuberculosis deaths could increase up to 20% in the next 
5 years.42,43 Physical-distancing and mask-wearing policies 
might help to reduce tuberculosis transmission, but 
this beneficial effect might be offset by increased 
opportunities for household transmission.44 Prolonged 
exposure to household contacts is an important risk 
factor for tuberculosis transmission, and the duration of 
infectiousness might be further extended if there are 
disruptions to tuberculosis treatment due to health 
system overload as a result of COVID-19. Tuberculosis 
programmes, once they have evaluated the impact of 
COVID-19 on tuberculosis for any severe setbacks, might 
need to consider the recalibration of global targets.
Overall, despite different estimation methods, the 
global burden of tuberculosis estimated by GBD is 
similar to that produced by WHO.3 A concern raised 
previously was that past iterations of GBD and 
WHO estimates produced discrepancies in estimated 
tuberculosis mortality.45 For example, in earlier iterations, 
GBD 20162 estimated 1·45 million tuberculosis deaths, 
whereas WHO 201746 estimated 1·67 million tuberculosis 
deaths in 2016. However, the latest estimates show that 
the differences are decreasing at the global level. 
Although GBD 2019 estimated slightly lower global 
incident cases at 9·65 million (95% UI 8·48–11·03) than 
WHO’s estimate of 10·0 million (9·0–11·1), both 
GBD 2019 and WHO estimated approximately 
1·40 million deaths in 2019 (1·40 million deaths by 
GBD 2019, and 1·39 million deaths by WHO). However, 
there are some differences in sex-specific estimates: 
GBD 2019 estimated that 56% of global incident 
tuberculosis cases and 65% of global tuberculosis deaths 
were among males, whereas, for the same year, WHO 
estimated that 63% of global incident tuberculosis cases 
and 61% of global tuberculosis deaths were among 
males. The higher percentage for tuberculosis mortality 
than for tuberculosis incidence in males in GBD 2019 
might be expected due to several factors, such as men 
presenting advanced stages of tuberculosis when care is 
sought and heightened exposure to risk factors.19,47–49 
Previous work has shown that smoking and alcohol 
consumption further contribute to poor tuberculosis 
treatment outcomes and compliance among men.47–49
The tuberculosis burden results should be interpreted 
in the context of the following limitations. First, there are 
gaps in data availability across countries, age groups, 
and time periods. In locations without reliable vital 
registration data, mortality estimates are driven by verbal 
autopsy studies, which have been shown to have modest 
sensitivity in identifying tuberculosis deaths.50–52 We 
believe that this bias has been minimised through 
excluding verbal autopsy studies from countries with high 
HIV burden. Second, because the GBD 2019 tuberculosis 
results are based on available data and modelling, lags in 
reporting of vital registration data indicate that 
tuberculosis mortality estimates for most recent years rely 
on modelling processes. Estimates for locations and years 
where data are sparse are reflected by wide UIs. Third, we 
have not yet been able to quantify the burden of 
tuberculosis attributable to indoor air pollution due to a 
lack of objectively measured longitudinal data.53 Similarly, 
the burden attributable to malnutrition has not yet been 
quantified because there is insufficient evidence of a 
causal relationship and limited data on the risk of 
tuberculosis across different levels of malnutrition.54 
Fourth, there are challenges in accurately estimating sex 
differences in tuberculosis burden due to the way age-sex-
specific estimates are reported in tuberculosis prevalence 
surveys. Prevalence surveys often report data separately by 
age (for both sexes combined) and by sex (for all ages 
combined). To extract age-sex-specific data from these 
surveys, we used the age distribution for both sexes in the 
study to split the all-age sex-specific data. Data extraction 
would be more accurate if tuberculosis prevalence surveys 
reported data by age and sex to improve modelling inputs. 
Finally, there remain major challenges in our statistical 
triangulation approach, in which there are difficulties in 
computing consistent estimates between tuberculosis 
death rates and prevalence data from national surveys. 
This is particularly problematic for locations in 
sub-Saharan Africa where there are few prevalence 
surveys or reliable cause of death data. Closer analyses 
have shown that even when prevalence and cause of death 
data are available, there are inconsistencies in the sources. 
In Bangladesh, for example, we found that a national 
prevalence survey55 estimated tuberculosis prevalence to 
be approximately 300 per 100 000 population, but verbal 
autopsy sources56,57 reported mortality rates of less than 10 
per 100 000 population. Together, the two sources suggest 
that Bangladesh has one of the lowest case fatality rates in 
the world for tuberculosis. In GBD 2019, we resolved 
inconsistencies in data sources by excluding less reliable 
sources that contradicted others.
GBD 2019 has made several methodological 
improvements compared with earlier GBD iterations.2,10 
First, we used a novel Bayesian meta-regression method 
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to incorporate uncertainty from the input data in 
our mortality-to-incidence ratio approach. Second, we 
addressed the potential for misclassification of tuberc-
ulosis deaths as pneumonia deaths for children younger 
than 15 years. We made this adjustment using data from 
a systematic review58–65 to redistribute pneumonia deaths 
in cause of death data to tuberculosis. Third, we 
standardised our adjustment to prevalence surveys that 
used smear-positive tuberculosis as the case definition 
rather than bacteriologically confirmed tuberculosis, 
while incorporating a novel adjustment to recalibrate 
studies that used symptoms only as the screening 
method compared with using both symptoms and chest 
x-ray. Finally, our statistical triangulation approach was 
improved by incorporating data on remission and excess 
mortality, while also resolving discrepancies in morbidity 
and mortality data.
As countries refine national tuberculosis programmes 
and strategies to end the tuberculosis epidemic, the 
excess burden experienced by males should be more 
widely realised and monitored. The greater incidence 
and mortality rates among men found in GBD 2019 
indicate that men are not fully accessing tuberculosis 
services and are remaining infectious in the community 
for substantial periods of time. Targeting the burden of 
disease in males will diminish the overall burden of 
tuberculosis and will be crucial in reaching both equity 
and burden targets outlined by the SDGs and the End TB 
Strategy. Furthermore, tuberculosis programmes should 
examine key risk factors that are contributing to 
disproportionate tuberculosis burden in males, such as 
alcohol and smoking, and liaise with risk factor control 
initiatives aiming to reduce alcohol use and smoking. 
Reaching equity goals will also require identifying and 
addressing inequalities in health facilities where women 
often encounter barriers to accessing tuberculosis 
diagnostic services. These efforts should occur in parallel 
with addressing risk factors for women’s vulnerability to 
HIV infection to minimise excess HIV and tuberculosis 
coinfection burden among females in the countries with 
highest HIV burden.
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